This is a U.S. news story, published by CNBC, that relates primarily to Cobenfy news.
For more U.S. news, you can click here:
more U.S. newsFor more Cobenfy news, you can click here:
more Cobenfy newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
schizophrenia drug Cobenfy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest anticipated schizophrenia drug news, Bristol Myers Squibb executives news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Bristol Myers SquibbCNBC
•
84% Informative
Cobenfy will cost $ 1,850 for a month 's supply or $ 22,500 annually before insurance and other rebates.
The drug is a badly needed new option for the nearly 3 million adults in the U.S. living with schizophrenia.
Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements.
Cobenfy met the main goal of three clinical trials, significantly decreasing symptoms of schizophrenia compared with a placebo.
The approval was based on data from three trials comparing Cobenf to a placebo, as well as two longer-term studies that examined how safe and tolerable the drug is for up to one year .
The company also plans to study the drug's potential to treat bipolar mania and irritability associated with autism.
VR Score
83
Informative language
83
Neutral language
37
Article tone
semi-formal
Language
English
Language complexity
64
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
6
Affiliate links
no affiliate links